Archived Monthly Oncology Tumor Boards: Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease
Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.
Category
  • Gastric/Esophageal Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
November 2022 BCOP Test - Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The test is available for an additional fee of $50. Each activity is this series is worth 1 hour of BCOP credit. Save $10 per test by purchasing the 12-test bundle!
Category
Format
Credits
NCCN Guidelines® Insights - Prostate Cancer, Version 1.2023
These NCCN Guidelines Insights summarizes much of the panel’s discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
Category
  • Prostate Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Management of Graft-Versus-Host Disease
Educating nurses in the identification of symptoms and the treatments available will increase the identification and early treatment of GVHD in patients.  Nurses are in a perfect position to include other team members to address the psychosocial and palliative/symptomatic care of patients with GVHD, both acute and chronic.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Implementation of a Hematology Outpatient Sepsis Alert Protocol
Quality initiatives directed at standardized clinical pathways for symptom management, and development for urgent cancer care tactics are becoming a standard in cancer care to help reduce sepsis and the need for acute care.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Palliative Care and Hematologic Malignancies: Can They Co-Exist?
Education on the use of palliative care resources is important to help hematology oncology clinicians potentially lessen the bias that may surround including “outsiders” in the care of their patients, thus allowing these patients and their caregivers to experience the benefits of this resource earlier in their care.
Category
  • Palliative Care
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Key Assessment and Evaluation Strategies After CAR T-Cell Therapy
The management of adverse effects, including toxicity from treatment as well as the education of patients and the coverage of these treatments by insurance are imperative to good clinical care of patients receiving these therapies.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
The Importance of Re-Vaccination After Cellular Therapy
Cellular therapies are associated with an increased infection risk, and vaccination in these survivors plays a critical role in lowering that risk. Clinicians need to be educated on the importance of vaccination in these survivors as well as the details of dosing and timing of vaccines to best protect this vulnerable population from vaccine-preventable diseases.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Treatment Decisions in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly transformed the treatment landscape of relapsed/refractory disease. The benefit/risk of continuous vs.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages